Drug improvement stays some of the capital-intensive actions in life sciences. A 2021 peer-reviewed research revealed in Clinical and Translational Science found that the success fee of a drug candidate from the beginning of scientific trials to advertising approval sits at roughly 10–20% and has not meaningfully modified in a long time. A separate evaluation…
This interview analysis is sponsored by AcuityMD and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page. The MedTech commercial sector in 2026 is defined by a paradox of data. While research and development complexity…
Life sciences are over‑funding AI and underneath‑funding the info maturity required to scale it. This imbalance is popping a possible R&D accelerant right into a excessive‑priced bottleneck that fails to ship compounding returns throughout the portfolio. These workflows depend on fragmented information sources spanning molecular databases, medical trial registries, inner protocols, and revealed literature. This…
Across regulated and asset-intensive industries, AI adoption is shaped by factors beyond technical feasibility. Organizations now seek to deploy AI systems that deliver measurable operational improvements. At the same time, they must keep these systems safe, explainable, and aligned with human judgment. Errors in these contexts carry real human and economic consequences. In manufacturing, these…
This interview analysis is sponsored by Deloitte and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page. Life sciences organizations stand at a paradoxical moment in AI adoption. The technology’s potential is visible in discovery,…
Clinical trials comprise the most significant portion of drug development costs. In some cases, drug R&D costs can approach as high as $2 billion per drug and are accompanied by protracted timelines of 10-15 years. Pharmaceutical companies are turning to AI to shorten discovery timelines while dramatically upholding rigorous standards. AI-driven approaches have demonstrated meaningful…
Generative AI has been accelerating transformation across the life sciences, leaving pharmaceutical companies and clinical research organizations facing a dual challenge: modernizing pharmacovigilance while maintaining uncompromising standards for patient safety, data integrity, and global regulatory compliance. This delicate balance is most critical in adverse event detection and signaling, where a single missed risk can trigger…
This interview evaluation is sponsored by Deloitte and was written, edited, and printed in alignment with our Emerj sponsored content guidelines. Learn extra about our thought management and content material creation providers on our Emerj Media Services page. In R&D-intensive sectors akin to life sciences, agriculture, and superior supplies, a well-recognized problem persists: fragmented information…
Roche Diagnostics is among the two essential divisions of mother or father firm F. Hoffman-La Roche AG, a Swiss multinational healthcare firm that focuses on prescription drugs and diagnostics. Roche Diagnostics’ North American headquarters is positioned in Indianapolis, Indiana. The division leverages superior applied sciences to reinforce its world service choices, significantly in optimizing provide…
In healthcare, affected person information is the basis of analysis, therapy, and belief. With digital well being programs and AI instruments turning into central to care supply, healthcare suppliers accumulate exponentially extra delicate affected person information. This information explosion has additionally expanded the assault floor, with nations adopting totally different frameworks and approaches to managing…